A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".
作者信息
Zeng Jing, Fan Jian-Gao
机构信息
Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):610-614. doi: 10.3350/cmh.2024.1099. Epub 2024 Dec 17.
Abstract
摘要
相似文献
1
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".在黑暗中迈出的一步：减重手术治疗代谢功能障碍相关脂肪性肝病相关性肝硬化：关于“减重手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”的社论
Clin Mol Hepatol. 2025 Apr;31(2):610-614. doi: 10.3350/cmh.2024.1099. Epub 2024 Dec 17.
2
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis.减重手术可降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率。
Clin Mol Hepatol. 2025 Jan;31(1):227-239. doi: 10.3350/cmh.2024.0564. Epub 2024 Nov 14.
3
Reply to correspondence on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".对关于“减肥手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”的信件的回复
Clin Mol Hepatol. 2025 Apr;31(2):e218-e220. doi: 10.3350/cmh.2025.0070. Epub 2025 Feb 3.
4
Correspondence to editorial on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".致关于“减重手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e173-e175. doi: 10.3350/cmh.2025.0001. Epub 2025 Jan 9.
5
Letter to the editor on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".致编辑的信：关于“减重手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”
Clin Mol Hepatol. 2025 Apr;31(2):e143-e144. doi: 10.3350/cmh.2025.0140. Epub 2025 Feb 18.
6
Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery.代谢性减重手术对非酒精性脂肪性肝病相关肝硬化的代偿作用
Trends Endocrinol Metab. 2025 Feb;36(2):118-132. doi: 10.1016/j.tem.2024.05.009. Epub 2024 Jun 21.
7
Letter to the editor on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".致编辑的信：关于“减重手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”
Clin Mol Hepatol. 2025 Jul;31(3):e247-e248. doi: 10.3350/cmh.2025.0073. Epub 2025 Feb 6.
8
Letter to the editor on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".致编辑的信：关于“减重手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”
Clin Mol Hepatol. 2025 Jul;31(3):e252-e253. doi: 10.3350/cmh.2025.0189. Epub 2025 Feb 26.
9
Therapeutic management of metabolic dysfunction associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的治疗管理。
United European Gastroenterol J. 2024 Mar;12(2):177-186. doi: 10.1002/ueg2.12525. Epub 2024 Jan 9.
10
Endoscopic bariatric and metabolic therapies and its effect on metabolic dysfunction-associated steatotic liver disease: a review of the current literature.内镜下减肥与代谢疗法及其对代谢功能障碍相关脂肪性肝病的影响：当前文献综述
Surg Obes Relat Dis. 2025 Feb;21(2):175-182. doi: 10.1016/j.soard.2024.09.012. Epub 2024 Oct 9.
引用本文的文献
1
Reply to correspondence on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".对关于“减肥手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”的信件的回复
Clin Mol Hepatol. 2025 Apr;31(2):e218-e220. doi: 10.3350/cmh.2025.0070. Epub 2025 Feb 3.
2
Correspondence to editorial on "Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis".致关于“减重手术降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e173-e175. doi: 10.3350/cmh.2025.0001. Epub 2025 Jan 9.
本文引用的文献
1
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).《代谢功能障碍相关脂肪性肝病防治指南（2024年版）》
J Clin Transl Hepatol. 2024 Nov 28;12(11):955-974. doi: 10.14218/JCTH.2024.00311. Epub 2024 Nov 4.
2
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis.减重手术可降低代谢功能障碍相关脂肪性肝病和肝硬化患者的长期死亡率。
Clin Mol Hepatol. 2025 Jan;31(1):227-239. doi: 10.3350/cmh.2024.0564. Epub 2024 Nov 14.
3
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
4
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.代谢相关脂肪性肝病：一种伴有心血管和恶性并发症的全身性代谢紊乱疾病。
Gut. 2024 Mar 7;73(4):691-702. doi: 10.1136/gutjnl-2023-330595.
5
Therapeutic management of metabolic dysfunction associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的治疗管理。
United European Gastroenterol J. 2024 Mar;12(2):177-186. doi: 10.1002/ueg2.12525. Epub 2024 Jan 9.
6
Lifestyle interventions in nonalcoholic fatty liver disease.非酒精性脂肪性肝病的生活方式干预。
Nat Rev Gastroenterol Hepatol. 2023 Nov;20(11):708-722. doi: 10.1038/s41575-023-00800-4. Epub 2023 Jul 4.
7
Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.治疗非酒精性脂肪性肝病相关肝硬化患者的当前挑战和未来展望。
Hepatology. 2024 Nov 1;80(5):1270-1290. doi: 10.1097/HEP.0000000000000456. Epub 2023 May 16.
8
Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.减重代谢手术与生活方式干预联合最佳药物治疗非酒精性脂肪性肝炎（BRAVES）：一项多中心、开放标签、随机试验。
Lancet. 2023 May 27;401(10390):1786-1797. doi: 10.1016/S0140-6736(23)00634-7. Epub 2023 Apr 21.
9
Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis.减重手术对不良肝脏结局的影响：系统评价和荟萃分析。
Surg Obes Relat Dis. 2023 Jul;19(7):717-726. doi: 10.1016/j.soard.2022.12.025. Epub 2022 Dec 21.
10
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
Zotero 插件